FIELD: medicine. SUBSTANCE: the present innovation deals with methods and compositions useful to suppress αvβ5-mediated angiogenesis. The method to suppress tissue αvβ5-mediated angiogenesis applies antagonists of αvβ5-vitronectin as monoclonal antibodies, RGD- containing polypeptide and organic mimetics. The advantage of the present innovation deals with applying mentioned inhibitors, especially in case of ocular neovascular diseases. EFFECT: higher efficiency. 29 cl, 14 dwg, 10 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TECHNIQUES AND COMPOSITIONS USED TO INHIBIT αβ-CAUSED ANGIOGENESIS | 1997 |
|
RU2195312C2 |
| METHODS AND COMPOSITIONS USED FOR INHIBITING ANGIOGENESIS | 1997 |
|
RU2194528C2 |
| METHODS AND COMPOSITION USEFUL FOR ANGIOGENESIS INHIBITION | 1995 |
|
RU2162712C2 |
| METHODS FOR TREATMENT OF TUMORS AND METASTASIS USING COMBINATION OF ANTI-ANGIOGENIC THERAPY AND IMMUNOTHERAPY | 2000 |
|
RU2236251C2 |
| SELECTIVE R-CADHERIN ANTAGONISTS AND METHODS | 2004 |
|
RU2349598C2 |
| ANTIBODIES FOR TREATING OPIOID ADDICTION | 2021 |
|
RU2841257C1 |
| REVASCULARISATION OF ISCHEMIC RETINAL TISSUE AND SCREENING TECHNIQUE | 2006 |
|
RU2401124C2 |
| POLYPEPTIDES DERIVED FROM TRYPTOPHANYL-TRNA-SYNTHETASE AND USES THEREOF IN CONTROLLING OF VASCULARISATION | 2002 |
|
RU2297425C2 |
| COMPOSITIONS OF ANTIBODIES AGAINST ROR1 AND CORRESPONDING METHODS | 2017 |
|
RU2766190C2 |
| MODULATORS OF ANGIOGENESIS AND VESSEL PERMEABILITY | 2000 |
|
RU2271216C2 |
